Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 5:24 PM
Ignite Modification Date:
2025-12-26 @ 5:24 PM
NCT ID:
NCT05694806
Eligibility Criteria:
Inclusion Criteria:
* Hematologic malignancy at diagnosis or relapse
* Symptomatic mediastinal mass syndrome
* Admission to the ICU, Continuous Medical Surveillance (CMS) or Intensive Care (IC) for symptomatology related to MMS
* Chest CT (after maximum 48 hours of corticosteroid therapy (1mg/kg/ Prednisone equivalent), maximum 15 days before and 5 days after admission to ICU)
* Maximum administration of corticosteroid therapy 48 hours before admission to the ICU (maximum 1mg/kg/ Prednisone equivalent)
* No prior pleural or pericardial drainage
* Study period: 01/01/2014 - 31/12/2021 (8 years)
Exclusion Criteria:
* No diagnosis of hematologic malignancy
* Diagnosis of solid benign or malignant tumor
* No mediastinal mass syndrome
* No admission to ICU/CMS
* No chest CT scan meeting inclusion criteria
* Administration of corticosteroids for more than 48 hours prior to admission to the ICU and/or prior to chest CT
* Lack of social security affiliation.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
16 Years
Study:
NCT05694806
Study Brief:
Protocol Section:
NCT05694806